Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
June 19 2008 - 8:30AM
PR Newswire (US)
GAITHERSBURG, Md. and VIENNA, June 19 /PRNewswire-FirstCall/ --
Iomai Corporation (NASDAQ:IOMI) announced that its Chief Scientific
Officer, Gregory Glenn, M.D., and Alexander Von Gabain, Ph. D., the
Chief Scientific Officer of Intercell AG (VSE: ICLL), will speak
today at the Biotechnology Industry Organization's International
Convention at a breakout session titled "Breakthrough Technologies,
Burgeoning Business." The session will begin at 4 p.m. in room 30A
of the San Diego Convention Center. As previously announced, Iomai
and Intercell AG have entered into an agreement whereby Iomai has
agreed to be acquired by Intercell AG. About Iomai Cooperation
Iomai Corporation discovers and develops vaccines and immune system
stimulants, delivered via a novel, needle-free technology called
transcutaneous immunization (TCI). TCI, discovered by researchers
at the Walter Reed Army Institute of Research, taps into the unique
benefits of a major group of antigen-presenting cells found in the
outer layers of the skin (Langerhans cells) to generate an enhanced
immune response. Iomai is leveraging TCI to enhance the efficacy of
existing vaccines, develop new vaccines that are viable only
through transcutaneous administration and expand the global vaccine
market. Iomai currently has four product candidates in development:
three targeting influenza and pandemic flu and one to prevent
travelers' diarrhea. For more information on Iomai, please visit
http://www.iomai.com/. Iomai announced on May 12 that it has
entered into an agreement with Intercell AG in which Intercell will
acquire Iomai for $6.60 a share. About Intercell AG Intercell AG is
a growing biotechnology company which focuses on the design and
development of novel vaccines for the prevention and treatment of
infectious diseases with substantial unmet medical need. The
Company develops antigens and adjuvants which are derived from its
proprietary technology platforms and has in-house GMP manufacturing
capabilities. Based on these technologies, Intercell has strategic
partnerships with a number of global pharmaceutical companies,
including Novartis, Merck & Co., Inc., Wyeth, Sanofi Pasteur,
Kirin, and the Statens Serum Institut. The Company's leading
product, a prophylactic vaccine against Japanese Encephalitis,
successfully concluded pivotal Phase III clinical trials in 2006.
The Market Authorization Application (MAA) in Europe as well as the
Biological License Application (BLA) with the US Food and Drug
Administration (FDA) for the use of the vaccine to prevent Japanese
Encephalitis were submitted in December of 2007. The licensure
application to TGA (Therapeutic Goods Administration) in Australia
was submitted in February of 2008. The Company's broad development
pipeline includes a partnered S. aureus vaccine in Phase II, a
therapeutic vaccine against Hepatitis C in Phase II, a Pseudomonas
vaccine in Phase II, a partnered Tuberculosis vaccine (Phase I/II),
and five products focused on infectious diseases in preclinical
development. Intercell is listed on the Prime Market of the Vienna
Stock Exchange under the symbol "ICLL". ISIN: AT0000612601 For more
information on Intercell, please visit: http://www.intercell.com/
DATASOURCE: Iomai Corporation CONTACT: Russell P. Wilson, SVP,
Chief Financial Officer and General Counsel of Iomai Corporation,
+1-301-556-4478, ; or Brian Reid of WeissComm Partners, Inc.,
+1-703-402-3626, , for Iomai Corporation; or Lucia Malfent, Head of
Corporate Communications for Intercell AG, +43-1-20620-303, Web
site: http://www.iomai.com/ http://www.intercell.com/
Copyright
Iomai Corp (MM) (NASDAQ:IOMI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Iomai Corp (MM) (NASDAQ:IOMI)
Historical Stock Chart
From Aug 2023 to Aug 2024